| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Jack W Callicutt is Chief Financial Officer at GALT. Jack W Callicutt's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $26K at current prices.
Our model assigns Jack W Callicutt a strong insider score of 71/100, based on 12 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +3.2%.
The GALT filings lean toward selling, a net 623,896 shares.
Jack W Callicutt has 27 Form 4 filings on record from January 2015 to January 2026, all as Chief Financial Officer at Galectin Therapeutics (GALT), 2015–2026.
The 77 reported transactions were 29 open-market sales, 28 option exercises, 17 option or other derivative awards and 3 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $15K and 12 sales worth about $4.0M.
The largest open-market purchase was 2,354 shares of GALT at an average $4.28 on May 31, 2019, about $10K.
The largest open-market sale was 226,000 shares of GALT at an average $8.61 on June 20, 2018, about $1.9M.
All 7 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 60,000 | $3.89 | $233,387.57 | -88.7% | -25.8% | - | |
| Nov 18, 2025 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 77,920 | $6.15 | $478,849.17 | -91.1% | -55.7% | - | |
| Nov 10, 2025 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 5,291 | $6.03 | $31,883.65 | -41.0% | -47.7% | - | |
| Nov 5, 2025 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 600 | $6.00 | $3,600.00 | -7.3% | -42.3% | - | |
| Nov 4, 2025 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 32,439 | $6.06 | $196,676.13 | -81.0% | -47.1% | - | |
| Sep 12, 2025 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 8,706 | $6.44 | $56,053.58 | -53.3% | +6.3% | -27.2% | |
| Dec 23, 2024 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE10b5-1 | 40,000 | $0.89 | $35,492.00 | -84.0% | +85.4% | +348.3% | |
| Nov 17, 2022 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Buy | 4,000 | $1.32 | $5,280.00 | +110.7% | +5.9% | +44.1% | |
| May 31, 2019 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Buy | 2,354 | $4.28 | $10,075.12 | +186.8% | - | - | |
| Jun 20, 2018 | GALT Galectin Therapeutics Inc | Chief Financial Officer | Sale+OE | 226,000 | $8.61 | $1,946,021.40 | -99.4% | - | - |